Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM).
Levo-alpha-acetylmethadol (LAAM) is an orphan drug that will soon be generally available to treatment facilities. We have recently treated 959 opioid addicts with LAAM for periods up to 36 consecutive months. Three times per week dosing of LAAM proved to be a safe and effective treatment agent for the majority of subjects. During LAAM induction there is a delay in opioid activity as LAAM forms its long-acting metabolites, therefore, symptomatic withdrawal medication must usually be administered during the first 96 hours of treatment to adequately suppress opioid withdrawal symptoms and prevent self-administration of drugs by the patient. No long-term hepatic toxicity or tumor formation could be demonstrated by liver function studies and liver-spleen imaging in a subgroup of patients. Some opioid addicts report that they prefer LAAM over methadone, but the reverse was reported by about 40% of our patients which suggests that both drugs are needed for adequate maintenance treatment of the opioid-addicted population.
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008691:Methadone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008692:Methadyl Acetate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009293:Opioid-Related Disorders / Q000188:drug therapy*
D008692:Methadyl Acetate; D008691:Methadone